Genor Biopharma Executive and Leadership Team

Feng Guo, the Chief Executive Officer at Genor Biopharma, directs the company's overarching strategy and vision. Guo guides the development and commercialization of oncology and autoimmune drugs, ensuring alignment with the mission to serve patients with innovative therapies. This leadership role involves overseeing the robust pipeline of 15 targeted drug candidates and driving the company's expansion, particularly within the Chinese market. Feng Guo's strategic direction ensures Genor Biopharma remains a key player, focusing on both proven and novel biological pathways to address critical unmet medical needs. The Chief Executive Officer's oversight extends to fostering research and development initiatives that solidify the company's global biopharmaceutical standing and commitment to societal benefit.

Weng Chengyi, the Executive Director & Chief Financial Officer at Genor Biopharma, directs the company's financial strategy and resource allocation. Chengyi manages all financial operations, including budgeting, forecasting, and investment, ensuring the fiscal health necessary to support the development of oncology and autoimmune drugs. This role is pivotal in securing funding and optimizing capital deployment for the company's robust pipeline of 15 targeted drug candidates. Weng Chengyi's financial acumen supports Genor Biopharma's mission to serve patients with innovative therapies by enabling sustained investment in research and development. The Executive Director & Chief Financial Officer's oversight ensures financial stability and strategic growth, reinforcing the company's position in the global biopharmaceutical market.

Paul Ni, the Chief Operating Officer (Genor Biopharma) at Genor Biopharma, executes the operational strategies that enable drug development and commercialization. Ni oversees the day-to-day functions critical to advancing the company's pipeline of oncology and autoimmune drugs, ensuring efficient processes from research through to market readiness. This leadership involves managing resources and optimizing workflows to support the successful development of drug candidates, particularly those with significant commercialization potential in China. Paul Ni's operational management ensures that Genor Biopharma can effectively serve patients with innovative therapies by maintaining high standards of execution. The Chief Operating Officer (Genor Biopharma)'s focus on operational excellence underpins the company's ability to impact society through reliable and timely delivery of treatments.

Qibin Liang, the Chief Technology Officer at Genor Biopharma, architects the technological infrastructure and innovation pipeline. Liang spearheads the research and development efforts, focusing on identifying and advancing targeted drug candidates for oncology and autoimmune diseases. This involves managing the company's robust pipeline of 15 drug candidates, ensuring scientific rigor and efficient progression through development stages. Qibin Liang's expertise is critical in exploring both proven and novel biological pathways, directly supporting Genor Biopharma's mission to deliver innovative therapies. The Chief Technology Officer's role is central to maintaining the company's competitive edge and its position as a significant contributor to the global biopharmaceutical landscape through cutting-edge scientific advancements.

Li Tong, the Chief Medical Officer at Genor Biopharma, leads the clinical development and medical affairs strategy for the company's therapeutic pipeline. Tong oversees the design and execution of clinical trials for oncology and autoimmune drug candidates, ensuring they meet rigorous scientific and regulatory standards. This involves guiding the progression of the company's 15 targeted drug candidates, focusing on demonstrating safety and efficacy to serve patients with innovative treatments. Li Tong's medical expertise is crucial in validating novel biological pathways and advancing drug candidates with significant commercialization potential, particularly in China. The Chief Medical Officer's leadership ensures Genor Biopharma's commitment to delivering impactful therapies and contributing positively to global health outcomes.